<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193593</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-MA201</org_study_id>
    <nct_id>NCT03193593</nct_id>
  </id_info>
  <brief_title>Study to Evaluate EB-001 in Reducing Musculoskeletal Pain</brief_title>
  <official_title>Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonti, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bonti, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of single intra-operative treatment of EB-001 IM&#xD;
      injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with&#xD;
      subpectoral implants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of EB-001 in decreasing post-surgical pain&#xD;
      in patients undergoing surgical breast augmentation with subpectoral placement of the&#xD;
      implants. Intramuscular (IM) injection of EB-001 into the PM bilaterally during surgery may&#xD;
      decrease pain related to stretching of the PM by the implants.&#xD;
&#xD;
      The safety objective is to determine the safety and tolerability of single intraoperative&#xD;
      treatment of EB-001 IM injections into the PM in subjects undergoing breast augmentation with&#xD;
      subpectoral implants.&#xD;
&#xD;
      The efficacy objective is to evaluate the efficacy of intraoperative administration of EB-001&#xD;
      IM into the PM in reducing the pain and use of rescue pain medications in subjects undergoing&#xD;
      breast augmentation with subpectoral implants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">August 7, 2018</completion_date>
  <primary_completion_date type="Actual">April 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</measure>
    <time_frame>16 hours to 96 hours following dosing</time_frame>
    <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebo&#xD;
Single Saline Injection into the Pectoralis Muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 2 (1.6X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 3 (3.3X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 4 (6.7X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 5 (10X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EB-001 Dose 6 (13.3X)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: EB-001&#xD;
6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo- Single injection of saline into Pectoralis Muscle</description>
    <arm_group_label>Placebo Injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB-001</intervention_name>
    <description>Single injection of EB-001 into Pectoralis Muscle</description>
    <arm_group_label>EB-001 Dose 1</arm_group_label>
    <arm_group_label>EB-001 Dose 2 (1.6X)</arm_group_label>
    <arm_group_label>EB-001 Dose 3 (3.3X)</arm_group_label>
    <arm_group_label>EB-001 Dose 4 (6.7X)</arm_group_label>
    <arm_group_label>EB-001 Dose 5 (10X)</arm_group_label>
    <arm_group_label>EB-001 Dose 6 (13.3X)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 18 to 55 years of age, inclusive&#xD;
&#xD;
          2. Women who are in good health as determined by medical history, physical examination,&#xD;
             clinical laboratory studies, ECGs, vital signs, and Investigator judgment&#xD;
&#xD;
          3. Scheduled to undergo primary breast augmentation under general anesthesia&#xD;
             (endotracheal or otherwise) with:&#xD;
&#xD;
               1. Sub-pectoral implants placement,&#xD;
&#xD;
               2. Infra-mammary surgical approach,&#xD;
&#xD;
               3. Implant size between 250 and 400cc and&#xD;
&#xD;
               4. Non-textured saline breast implants&#xD;
&#xD;
          4. American Society of Anesthesiologist (ASA) Physical Class 1-2&#xD;
&#xD;
          5. Women of non-childbearing potential or postmenopausal (at least 12 consecutive months&#xD;
             of amenorrhea)&#xD;
&#xD;
          6. Women of childbearing potential must not be pregnant, lactating, or planning to become&#xD;
             pregnant during the study&#xD;
&#xD;
          7. Women of childbearing potential agreeing to use either:&#xD;
&#xD;
               1. a highly effective method of contraception with failures rates less than 1% per&#xD;
                  year such as implant, intrauterine device (IUD), or confirmed sterilization and&#xD;
                  sterilization procedure at least 3 months prior to the day of dosing&#xD;
&#xD;
               2. dual methods of contraception with overall failures rate less than 1% per year&#xD;
                  such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3&#xD;
                  months (subjects using oral contraception must have initiated treatment at least&#xD;
                  2 months prior to the day of dosing)&#xD;
&#xD;
          8. Willing and able to complete protocol requirements and instructions, which includes&#xD;
             completion of all required visits, procedures and in-clinic stays until the end of the&#xD;
             study&#xD;
&#xD;
          9. Willing and able to sign and date IRB-approved informed consent&#xD;
&#xD;
         10. Able to speak, read, and understand the language of the informed consent form (ICF)&#xD;
             and study questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of surgical procedure involving the breast, including, but not limited to,&#xD;
             breast augmentation. History of minor localized breast biopsy is not exclusionary if&#xD;
             it occurred at least 1 year prior to the screening visit, and if considered not&#xD;
             clinically significant in the opinion of the investigator.&#xD;
&#xD;
          2. Pre-existing lung disease that could impact subject safety in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          3. History of smoking within the past two years&#xD;
&#xD;
          4. Slow vital capacity that is below 80% of normal value for respective race, age,&#xD;
             height, and gender&#xD;
&#xD;
          5. Pulse oximetry below 95%&#xD;
&#xD;
          6. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of ≥ 32&#xD;
&#xD;
          7. Documented diagnosis of chronic pain condition, or other painful pre-operative&#xD;
             condition that, in the opinion of the investigator, may require analgesic treatment in&#xD;
             the post-operative period (e.g. significant joint pain, neuropathic pain)&#xD;
&#xD;
          8. Known hypersensitivity to any botulinum toxin serotype or to any component of the&#xD;
             formulation&#xD;
&#xD;
          9. Reported use of any botulinum toxin within 3 months prior to the date of surgery&#xD;
&#xD;
         10. Anticipated use of any botulinum toxin of any serotype during the study&#xD;
&#xD;
         11. Use of long acting opioids within 3 days or any opioid medication within 24 hours&#xD;
             prior to surgery&#xD;
&#xD;
         12. Aminoglycoside intake within 48 hours prior to or during surgery&#xD;
&#xD;
         13. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-&#xD;
             Lambert syndrome, or amyotrophic lateral Sclerosis)&#xD;
&#xD;
         14. Any past or current medical condition that in opinion of investigator, puts subject at&#xD;
             undue safety risk for surgical complications or for use of the investigational&#xD;
             product.&#xD;
&#xD;
         15. Any clinically significant psychiatric condition that, in opinion of investigator, may&#xD;
             interfere with study assessments or protocol compliance&#xD;
&#xD;
         16. History of alcohol or drug abuse in the last 3 years, based on investigator judgement&#xD;
&#xD;
         17. Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into&#xD;
             this study&#xD;
&#xD;
         18. Subject plans to donate blood or plasma from 30 days prior to screening until last&#xD;
             follow-up visit (Day 29)&#xD;
&#xD;
         19. Reported pain score of 2 or more at screening on the 11-point scale NPRS-A following&#xD;
             strength testing with PM activation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <results_first_submitted>October 17, 2018</results_first_submitted>
  <results_first_submitted_qc>January 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03193593/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="P2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.&#xD;
Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="P3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="P7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="B2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.&#xD;
Single Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="B3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.&#xD;
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.&#xD;
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.&#xD;
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.&#xD;
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.&#xD;
Single Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="16"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="4.66"/>
                    <measurement group_id="B2" value="29.5" spread="4.36"/>
                    <measurement group_id="B3" value="28.8" spread="6.08"/>
                    <measurement group_id="B4" value="27.0" spread="3.37"/>
                    <measurement group_id="B5" value="27.3" spread="4.30"/>
                    <measurement group_id="B6" value="27.3" spread="3.14"/>
                    <measurement group_id="B7" value="27.3" spread="3.14"/>
                    <measurement group_id="B8" value="27.6" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.57" spread="2.596"/>
                    <measurement group_id="B2" value="23.95" spread="2.958"/>
                    <measurement group_id="B3" value="23.00" spread="3.614"/>
                    <measurement group_id="B4" value="22.40" spread="2.848"/>
                    <measurement group_id="B5" value="22.66" spread="2.630"/>
                    <measurement group_id="B6" value="22.94" spread="2.117"/>
                    <measurement group_id="B7" value="23.18" spread="2.474"/>
                    <measurement group_id="B8" value="23.00" spread="2.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</title>
        <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
        <time_frame>16 hours to 96 hours following dosing</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Injections</title>
            <description>Placebo Injection into the Pectoralis Muscle</description>
          </group>
          <group group_id="O2">
            <title>EB-001 Dose 1 (1X)</title>
            <description>1st Dose in escalation paradigm.&#xD;
Injection of active drug into the pectoralis muscle</description>
          </group>
          <group group_id="O3">
            <title>EB-001 Dose 2 (1.6X)</title>
            <description>2nd Dose in escalation paradigm, 1.6X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O4">
            <title>EB-001 Dose 3 (3.3X)</title>
            <description>3rd Dose in escalation paradigm, 3.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O5">
            <title>EB-001 Dose 4 (6.7X)</title>
            <description>4th Dose in escalation paradigm, 6.7X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O6">
            <title>EB-001 Dose 5 (10X)</title>
            <description>5th Dose in escalation paradigm, 10X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
          </group>
          <group group_id="O7">
            <title>EB-001 Dose 6 (13.3X)</title>
            <description>6th Dose in escalation paradigm, 13.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)</title>
          <description>Subject's assessment of pain using the Numeric Pain Rating Scale (1= No Pain, 10= Maximum Pain) for the first 96 hours following injection, expressed as AUC over the 16h to 96h period following dosing.</description>
          <population>mITT</population>
          <units>units on a Scale*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.18" spread="211.552"/>
                    <measurement group_id="O2" value="341.78" spread="124.655"/>
                    <measurement group_id="O3" value="401.75" spread="310.509"/>
                    <measurement group_id="O4" value="290.55" spread="224.966"/>
                    <measurement group_id="O5" value="333.44" spread="217.742"/>
                    <measurement group_id="O6" value="381.82" spread="199.401"/>
                    <measurement group_id="O7" value="340.89" spread="155.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Injections</title>
          <description>Placebo Injection into the Pectoralis Muscle</description>
        </group>
        <group group_id="E2">
          <title>EB-001 Dose 1 (1X)</title>
          <description>1st Dose in escalation paradigm.&#xD;
Injection of active drug into the pectoralis muscle</description>
        </group>
        <group group_id="E3">
          <title>EB-001 Dose 2 (1.6X)</title>
          <description>2nd Dose in escalation paradigm, 1.6X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E4">
          <title>EB-001 Dose 3 (3.3X)</title>
          <description>3rd Dose in escalation paradigm, 3.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E5">
          <title>EB-001 Dose 4 (6.7X)</title>
          <description>4th Dose in escalation paradigm, 6.7X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E6">
          <title>EB-001 Dose 5 (10X)</title>
          <description>5th Dose in escalation paradigm, 10X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
        <group group_id="E7">
          <title>EB-001 Dose 6 (13.3X)</title>
          <description>6th Dose in escalation paradigm, 13.3X Dose 1.&#xD;
Injection of active drug into the pectoralis muscle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wajdie Ahmad</name_or_title>
      <organization>Bonti</organization>
      <phone>9493796569</phone>
      <email>wajdie@bonti.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

